Use of Sodium Bicarbonate As Prophylaxis for Kidney Damage in Patients with Heatstroke
Launched by HOSPITAL GENERAL DE MEXICALI · Sep 30, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether sodium bicarbonate (a common ingredient in baking soda) can help prevent kidney damage in patients who experience heatstroke, particularly those who have high levels of a muscle enzyme called CPK. The study is taking place at the General Hospital of Mexicali during the summer months and aims to see if giving sodium bicarbonate can reduce the risk of needing dialysis, a treatment for severe kidney failure.
To participate in this trial, individuals must be admitted to the hospital with heatstroke, which is defined as having a body temperature above 40 degrees Celsius and a CPK level greater than 1000 U/L. Participants will be those aged 65 to 74, and both men and women are welcome to join. Those who do not have a confirmed diagnosis of heatstroke or lack kidney function information at the time of admission will not be eligible. If you or a loved one meet these criteria, this trial may offer a potential way to protect kidney health during recovery from heat-related illnesses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to the General Hospital of Mexicali with the diagnosis of heat stroke.
- • Meeting the operational definition (exposure to heat, body temperature at admission greater than 40 degrees Celsius).
- • CPK level greater than 1000 U/L.
- • Having informed consent from the patient or the legally responsible adult.
- Exclusion Criteria:
- • Exclusion of the heat stroke diagnosis during their evaluation.
- • Lack of serum creatinine levels at the time of admission to the protocol.
About Hospital General De Mexicali
Hospital General de Mexicali is a leading healthcare institution committed to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical studies, the hospital focuses on a wide range of therapeutic areas, leveraging its state-of-the-art facilities and multidisciplinary expertise. With a dedication to ethical standards and patient safety, Hospital General de Mexicali aims to contribute to the development of new treatments and therapies, enhancing the overall health outcomes for the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mexicali, Baja California, Mexico
Patients applied
Trial Officials
Hiram J Jaramillo Ramirez, MD
Principal Investigator
Hospital General de Mexicali
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported